- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07509645
Effectiviteit en veiligheid van interleukine-6-receptorremmer gecombineerd met endovasculaire behandeling bij patiënten met acute posterieure circulatie beroerte door grote vatenocclusie (IRIS-3)
Effectiviteit en veiligheid van interleukine-6-receptorremmer gecombineerd met endovasculaire behandeling bij patiënten met acute posterieure circulatie grote vaten occlusie beroerte: Een gerandomiseerde, dubbelblinde, placebo-gecontroleerde klinische studie-3
This is an investigator-initiated phase III clinical trial employing a randomized, double-blind, placebo-controlled design. The primary objective of this study is to investigate the efficacy and safety of an interleukin-6 inhibitor (tocilizumab) combined with endovascular therapy in patients with acute posterior circulation large-vessel occlusion stroke.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
This is an investigator-initiated, prospective, multicenter phase III clinical trial. This trial aims to investigate whether tocilizumab could further improve prognosis for patients with acute posterior circulation large-vessel occlusion stroke receiving endovascular therapy.
Studietype
Inschrijving (Geschat)
Fase
- Fase 3
Contacten en locaties
Studiecontact
- Naam: Xunming Ji
- Telefoonnummer: 01083198962
- E-mail: jixm@ccmu.edu.cn
Studie Contact Back-up
- Naam: Chuanjie Wu
- Telefoonnummer: 01083199439
- E-mail: wuchuanjie@ccmu.edu.cn
Studie Locaties
-
-
-
Beijing, China, 100053
- Werving
- Capital Medical Univercity Xuanwu Hospital
-
-
Anhui
-
Huaibei, Anhui, China, 235100
- Werving
- Suixi County Hospital
-
Contact:
- Jianqiao Li
-
Suzhou, Anhui, China, 234000
- Werving
- Suzhou Municipal Hospital
-
Contact:
- Zhengfei Ma
-
-
Guangdong
-
Heyuan, Guangdong, China, 517000
- Werving
- Heyuan People's Hospital
-
Contact:
- Guanghong Zhong
-
Maoming, Guangdong, China, 525100
- Werving
- Huazhou People's Hospital
-
Contact:
- Yanbo Huang
-
-
Hebei
-
Qinhuangdao, Hebei, China, 066000
- Werving
- Qinhuangdao Second People's Hospital
-
Tangshan, Hebei, China, 063000
- Werving
- Tangshan Gongren Hospital
-
Contact:
- Jing Liu
-
Tangshan, Hebei, China, 064100
- Werving
- Yutian County Hospital
-
Contact:
- Haijun Li
-
-
Henan
-
Anyang, Henan, China, 455000
- Werving
- Anyang People's Hospital
-
Contact:
- Jiangang Zhang
-
Hebi, Henan, China, 456250
- Werving
- Junxian People's Hospital
-
Contact:
- Beibei Jiang
-
Luoyang, Henan, China, 471000
- Werving
- Luoyang Central Hospital
-
Contact:
- Wenbo Li
-
Nanyang, Henan, China, 473000
- Werving
- Nanyang Central Hospital
-
Contact:
- Yifeng Liu
-
Puyang, Henan, China, 457000
- Werving
- Puyang Oiled General Hospital
-
Contact:
- Yutie Zhao
-
Shangqiu, Henan, China, 476000
- Werving
- Shangqiu First People's Hospital
-
Contact:
- Quande Dai
-
Shangqiu, Henan, China, 476700
- Werving
- Ningling County Hospital
-
Contact:
- Xiaoyin Liu
-
Xinxiang, Henan, China, 453000
- Werving
- The First Affiliated Hospital of Henan Medical University
-
Contact:
- Hongkai Cui
-
Zhoukou, Henan, China, 466300
- Werving
- Shenqiu County Hospital
-
Contact:
- Yanling Li
-
Zhoukou, Henan, China, 466600
- Werving
- People's Hospital of Xihua
-
Contact:
- Chaoqun Li
-
-
Hubei
-
Xiangyang, Hubei, China, 441000
- Nog niet aan het werven
- Xiangyang First People's Hospital
-
Contact:
- Xiaolong Li
-
-
Hunan
-
Guankou, Hunan, China, 410300
- Werving
- Liuyang Jili Hospital
-
Contact:
- Yuzhang Bei
-
-
Jiangsu
-
Yancheng, Jiangsu, China, 224000
- Werving
- Yancheng First People's Hospital
-
Contact:
- Xiaofeng Qu
-
-
Shandong
-
Linyi, Shandong, China, 276000
- Werving
- People's Hospital of Linyi
-
Contact:
- Hao Wang
-
Zibo, Shandong, China, 255000
- Werving
- Zibo Central Hospital
-
Contact:
- Liangjie Wang
-
-
Shanxi
-
Xianyang, Shanxi, China, 712000
- Werving
- Xianyang First People's Hospital
-
Contact:
- Xingyun Yuan
-
Yuncheng, Shanxi, China, 044000
- Werving
- Yuncheng Central Hospital
-
Contact:
- Bin Wang
-
-
Zhejiang
-
Jiaxing, Zhejiang, China, 314000
- Werving
- Jiaxing First People's Hospital
-
Contact:
- Junjie Xu
-
Lishui, Zhejiang, China, 323000
- Werving
- Lishui Central Hospital
-
Contact:
- Xiao Peng
-
Taizhou, Zhejiang, China, 318000
- Werving
- Taizhou enze Hospital
-
Contact:
- Shaoqing Jiang
-
Wenzhou, Zhejiang, China, 325000
- Werving
- Wenzhou People's Hospital
-
Contact:
- Cheng Zhang
-
Yueqing, Zhejiang, China, 325600
- Werving
- People's Hospital of Yueqing
-
Contact:
- Saizhen Wu
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Age 18 years or older, of either sex;
- Acute ischemic stroke caused by occlusion of the basilar artery;
- Decide to undergo emergency endovascular treatment;
- Time from stroke onset to groin puncture within 24 hours;
- National Institutes of Health Stroke Scale (NIHSS) ≥ 10;
- Posterior circulation Alberta Stroke Program Early computed tomography score (pc-ASPECTS) ≥ 6;
- Signed informed consent from the patients or the legally authorized representatives.
Exclusion Criteria:
- Intracerebral hemorrhage, epidural hematoma, subdural hematoma, intraventricular hemorrhage, or subarachnoid hemorrhage;
- Pre-stroke modified Rankin scale (mRS) score >1;
- Known allergy to tocilizumab or excipients;
- Known allergy to iodinated contrast agents;
- Anticipated difficulty in completing endovascular treatment due to vascular tortuosity;
- History of congenital or acquired bleeding disorders, coagulation factor deficiency diseases, or thrombocytopenic diseases;
- Systolic blood pressure ≥180 mmHg or diastolic blood pressure ≥110 mmHg despite blood pressure control;
- Neutrophils < 2 × 10^9 /L;
- Platelets < 100 × 10^9 /L;
- Blood glucose <2.8 mmol/L (50 mg/dL) or >22.2 mmol/L (400 mg/dL);
- Serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels >2 times the upper limit of normal;
- Known recent or current serum creatinine >2 times the upper limit of normal or estimated glomerular filtration rate (eGFR) <60 mL/min;
- Pregnant, lactating, or planning pregnancy within 90 days;
- Severe mental disorders or inability to comply with informed consent and follow-up requirements due to dementia;
- Concurrent malignant tumors or severe systemic diseases with expected survival of less than 90 days;
- Presence of autoimmune diseases or use of immunosuppressive drugs;
- Systemic infectious diseases;
- Participation in another interventional clinical study within 30 days before randomization or currently participating in another interventional clinical study;
- Any circumstance that, as assessed by the investigators, might result in harm to the patients if study therapy is initiated;
- Other conditions that the investigator considers might affect compliance or preclude participation in this study.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Verviervoudigen
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Tocilizumab
Endovascular treatment combined with a 240mg tocilizumab injection once |
240 mg of tocilizumab injection will be diluted in 0.9% NaCl to a total volume of 100 mL. The solution will be administered via intravenous infusion immediately after randomization and no later than 30 minutes, with an infusion duration of more than 1 hour. |
|
Placebo-vergelijker: Placebo
Endovascular treatment combined with placebo |
An equivalent volume of placebo will be diluted in 0.9% NaCl to a total volume of 100 mL. The solution will be administered via intravenous infusion immediately after randomization and no later than 30 minutes, with an infusion duration of more than 1 hour. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Proportion of patients with a modified Rankin Scale (mRS) score of 0-3 at 90 days.
Tijdsspanne: 90 days
|
The mRS ranges from 0 to 6, with higher scores indicating worse outcomes. |
90 days
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Proportion of Barthel Index (BI) 95-100
Tijdsspanne: 90 days and 1 year
|
90 days and 1 year
|
|
|
mRS score distribution
Tijdsspanne: 90 days and 1 year
|
The mRS ranges from 0 to 6, with higher scores indicating worse outcomes. |
90 days and 1 year
|
|
Early neurological improvement at 24 hours
Tijdsspanne: 24 hours
|
Defined as a reduction in NIHSS score of at least 8 points from baseline or a score of 0 to 2 |
24 hours
|
|
NIHSS score at 7 days or at early discharge
Tijdsspanne: 7 days
|
The NIHSS ranges from 0 to 42, with higher scores indicating worse outcomes |
7 days
|
|
Proportion of patients with mRS score 0-1
Tijdsspanne: 90 days and 1 year
|
The mRS ranges from 0 to 6, with higher scores indicating worse outcomes. |
90 days and 1 year
|
|
Proportion of patients with mRS score 0-2
Tijdsspanne: 90 days and 1 year
|
The mRS ranges from 0 to 6, with higher scores indicating worse outcomes. |
90 days and 1 year
|
|
Proportion of patients with mRS score 0-4
Tijdsspanne: 90 days and 1 year
|
The mRS ranges from 0 to 6, with higher scores indicating worse outcomes. |
90 days and 1 year
|
|
EQ-5D-5L
Tijdsspanne: 90 days and 1 year
|
The EQ-5D-5L comprises the same five dimensions: MOBILITY, SELF-CARE, USUAL ACTIVITIES, PAIN / DISCOMFORT and ANXIETY / DEPRESSION, each dimension has five response levels: no problems, slight problems, moderate problems, severe problems, unable to/extreme problems. |
90 days and 1 year
|
Andere uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Incidentie van symptomatische intracraniële bloeding binnen 24 uur
Tijdsspanne: 24 uur
|
24 uur
|
|
|
Incidentie van intracraniële bloeding binnen 24 uur
Tijdsspanne: 24 uur
|
24 uur
|
|
|
Aandeel patiënten met longontsteking na 7 dagen of bij vroege ontslag
Tijdsspanne: 7 dagen
|
7 dagen
|
|
|
Mortality
Tijdsspanne: 90 days and 1 year
|
90 days and 1 year
|
|
|
Proportion of patients with a modified Rankin Scale (mRS) score of 0-3
Tijdsspanne: 1 year
|
The mRS ranges from 0 to 6, with higher scores indicating worse outcomes. |
1 year
|
Medewerkers en onderzoekers
Sponsor
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- IRIS-3
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
Related data will be shared if full study protocol and statistical analysis plan are provided with reasonable design.
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
product vervaardigd in en geëxporteerd uit de V.S.
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .